Research in ALS

Amyotrophic Lateral Sclerosis (ALS) remains one of the most challenging neurodegenerative diseases, with limited treatment options and no known cure. At Horgen Med, we are dedicated to transforming the landscape of ALS research through cutting-edge science, patient-centered studies, and strategic collaborations with global pharmaceutical and biotech companies. Our research focuses on understanding disease mechanisms, developing innovative therapies, and accelerating clinical trials to bring new hope to ALS patients worldwide.

Our Research Approach

Horgen Med’s approach to ALS research is built on a foundation of scientific excellence, collaboration, and innovation. Our research process follows a structured and multidisciplinary framework:

1. Understanding Disease Mechanisms

We invest heavily in studying the underlying cellular and molecular causes of ALS. Our research focuses on:

• Genetic factors, including mutations in genes like SOD1, C9orf72, and FUS
• Neuronal degeneration mechanisms, such as oxidative stress and mitochondrial dysfunction
• Protein misfolding and aggregation, a key factor in ALS progression
• Inflammatory responses and their role in motor neuron death

By mapping disease pathways and identifying biomarkers, we aim to develop targeted interventions that slow or halt disease progression.

2. Drug Discovery and Preclinical Studies

Horgen Med utilizes high-throughput drug screening and advanced computational modeling to identify promising compounds that could be effective against ALS. Our preclinical research includes:

• Testing neuroprotective drugs that prevent motor neuron degeneration
• Gene therapy research aimed at correcting mutations linked to ALS
• Stem cell-based approaches to regenerate damaged neurons

These efforts have led to the identification of several promising drug candidates, setting the stage for further clinical evaluation.

3. Clinical Trials and Patient-Centered Research

Horgen Med is deeply involved in clinical trial design and execution, ensuring that new treatments undergo rigorous testing for safety and efficacy. Our clinical research includes:

• Early-phase trials to evaluate novel drug formulations
• Biomarker-driven studies to personalize treatments based on patient genetics
• Longitudinal studies to track disease progression and treatment response

Our patient-first approach ensures that trials are designed to improve quality of life while advancing the search for effective therapies.

Key Advancements in ALS Research at Horgen Med

Horgen Med has achieved significant milestones in ALS research, contributing to groundbreaking advancements in treatment and disease understanding. Some of our most notable achievements include:

1. Development of Albrioza (AMX0035) as a Breakthrough Therapy

Horgen Med played a pivotal role in the development and clinical trials of Albrioza (AMX0035), a combination drug that has shown significant benefits in slowing ALS progression. Our research helped validate the drug’s ability to protect motor neurons, leading to regulatory approvals and increased accessibility for patients worldwide.

2. Collaboration in the Development of Riluzole

We worked closely with Sanofi and other pharmaceutical partners to optimize and enhance the effectiveness of Riluzole, the first FDA-approved drug for ALS. Our research helped refine its usage and identify patient subgroups that benefit the most from the treatment.

3. Advancements in Biomarker Research

Our team has discovered novel biomarkers that improve early ALS diagnosis and help track disease progression. These biomarkers are now being used in clinical trials to accelerate drug development and enable more personalized treatment approaches.

4. Breakthroughs in Gene Therapy

Horgen Med has been at the forefront of gene therapy research, developing innovative approaches to target genetic mutations associated with ALS. Our work has led to promising experimental therapies that may one day provide long-term solutions for genetically linked ALS cases.

Shaping the Future of ALS Treatment

At Horgen Med, we believe that collaboration, innovation, and relentless scientific pursuit will ultimately lead to a cure for ALS. Our ongoing research efforts focus on:

• Expanding clinical trials to test new drug combinations
• Exploring AI-driven research to uncover novel therapeutic targets
• Enhancing patient support programs through real-world data collection

By pushing the boundaries of medical research, we are bringing ALS patients closer to better treatments, improved quality of life, and, ultimately, a cure.

Join Us in the Fight Against ALS

Horgen Med is committed to accelerating the development of life-changing ALS treatments. Whether through research partnerships, clinical trials, or patient advocacy, we invite scientists, pharmaceutical companies, and patient communities to join us in this mission.

Together, we can make a lasting impact in the fight against ALS.